SCHEMBL6207085

SCHEMBL6207085

CCCCCc1ccc(-c2ccc(S(=O)(=O)C3(C(=O)NOC4CCCCO4)CCOCC3)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 11/20 0.43
MMP9 P14780 7/20 0.43
MMP1 P03956 3/20 0.43
ADAM17 P78536 1/20 0.43
MMP2 P08253 10/20 0.40
MMP8 P22894 9/20 0.40
MMP3 P08254 6/20 0.40
MMP7 P09237 4/20 0.40
RAB9A P51151 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 4/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
STAT3 P40763 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8313534 0.89 MMP13 (0.39) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL8313537 0.87 MMP13 (0.38) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL5908685 0.86 MMP13 (0.41) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL8316626 0.85 RAB9A (0.39) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL6227060 0.84 MMP13 (0.43) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL6697955 0.83 MMP13 (0.60) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL8321550 0.83 MMP13 (0.36) MMP13MMP9MMP1ADAM17MMP2
Hydrochloric Acid SCHEMBL6206733 0.82 MMP13 (0.59) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL6251227 0.82 RAB9A (0.51) MMP13MMP9MMP1ADAM17MMP2
SCHEMBL5908511 0.80 MMP13 (0.42) MMP13MMP9MMP1ADAM17MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565459-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS Pharmacia Corporation (US) 2005-08-24 EP disclosed
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors PHARMACIA CORPORATION 2004-07-22 US disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed
WO-2004048368-A2 HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142979-A1 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors MMP3, MMP13, MMP10 MMP13 2/4885MMP9 7/4885MMP1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.